Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold
Wall Street Zen has downgraded KalVista Pharmaceuticals (NASDAQ:KALV) from a "Buy" to a "Hold" rating. Despite this downgrade, the stock maintains a MarketBeat consensus of "Moderate Buy" with a target price of $32.60, based on seven Buy ratings and one Sell rating from other analysts. Insider activity shows sales totaling approximately $4.21 million in the last quarter, with insiders now owning 4.3% of the company.
Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next
KalVista Pharmaceuticals (KALV) saw its stock rise 5.0% following promising interim results from its KONFIDENT-KID trial for EKTERLY (sebetralstat) in pediatric hereditary angioedema (HAE). The oral tablet showed rapid symptom relief and no serious adverse events in children aged 2-11, addressing a significant unmet need in HAE care. This positive data strengthens the investment outlook for KalVista, particularly ahead of a planned pediatric NDA in Q3 2026, though high costs and potential payer constraints remain key risks.
A Look At KalVista Pharmaceuticals (KALV) Valuation After Positive KONFIDENT KID EKTERLY Trial Update
KalVista Pharmaceuticals (KALV) is receiving renewed attention following positive interim clinical trial data for EKTERLY, their oral hereditary angioedema treatment. Despite a recent net loss, the company has seen significant stock price growth over the past year. Analysts have varied valuations, with some suggesting the stock is undervalued based on EKTERLY's global rollout potential, while others caution about its high sales multiple compared to the industry average.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals announced that its Compensation Committee granted inducement options to five new employees. These options, totaling 66,375 shares of common stock, were granted on April 1, 2026, with an exercise price equal to the closing price of KalVista common stock on the first reported closing price following the grant. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to a four-year vesting schedule.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts
KalVista Pharmaceuticals (NASDAQ:KALV) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $32.60. Despite several analysts raising their price targets, the company has seen significant insider selling, with 248,009 shares valued at $4.21 million sold in the last three months. The stock opened at $20.13 and is trading near its 52-week high, with a market capitalization of $1.03 billion.
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial
KalVista Pharmaceuticals (KALV) saw a 22.4% stock increase following positive interim results from its KONFIDENT-KID trial for pediatric hereditary angioedema (HAE). The oral drug EKTERLY showed rapid and well-tolerated treatment in children aged 2-11, a group currently reliant on injectables. This success strengthens KalVista's investment narrative, with a US pediatric new drug application planned for Q3 2026, though the company still faces challenges in ensuring future revenues cover its significant expenses.
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals announced positive interim Phase 3 data from its KONFIDENT-KID trial for EKTERLY (sebetralstat) in children aged 2-11 with hereditary angioedema (HAE). The results, presented at the 2026 Global Angioedema Leadership Conference, showed that sebetralstat, an oral disintegrating tablet, enabled early and effective treatment of HAE attacks with a favorable safety profile. If approved, sebetralstat would be the first and only oral on-demand therapy for this pediatric population.
Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV
Hennion & Walsh Asset Management Inc. significantly increased its stake in KalVista Pharmaceuticals, Inc. by 93.6% in the fourth quarter of the previous year, now owning 341,819 shares valued at approximately $5.52 million. This move aligns with a "Moderate Buy" consensus rating from Wall Street analysts, with an average price target of $32.60, despite recent net selling by company insiders. The article details other institutional investments, analyst ratings, stock performance, and recent insider transactions.
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From EKTERLY Study
KalVista Pharmaceuticals has released positive interim Phase 3 data from its KONFIDENT-KID clinical trial for EKTERLY (sebetralstat), an on-demand treatment for hereditary angioedema (HAE) attacks in pediatric participants. The data indicates rapid symptom relief, with most attacks improving in about 1.5 hours and resolving in about 12 hours for the 150 mg dose group. KalVista plans to file a new drug application in the US in Q3 2026, with a launch expected in 2027.
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals has announced positive interim Phase 3 data from its KONFIDENT-KID trial for EKTERLY (sebetralstat), an on-demand oral treatment for hereditary angioedema (HAE) attacks in children aged 2-11. The data, presented at the 2026 Global Angioedema Leadership Conference, showed sebetralstat enabled early and effective treatment with a favorable safety profile, addressing a critical need for non-injectable HAE treatments in pediatric patients. KalVista anticipates filing a new drug application in the US in Q3 2026, aiming for a 2027 launch to provide the first oral on-demand therapy for this age group.
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals announced positive interim Phase 3 data from its KONFIDENT-KID trial for EKTERLY® (sebetralstat) in children aged 2-11 with hereditary angioedema (HAE). The data presented at the 2026 Global Angioedema Leadership Conference showed sebetralstat, an oral disintegrating tablet, enabled early and effective treatment of HAE attacks with a favorable safety profile, addressing a critical need for non-injectable options in pediatric patients. KalVista aims to file a new drug application in the US in Q3 2026, with a potential launch in 2027, making EKTERLY® the first and only oral on-demand therapy for this age group if approved.
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $42
Stifel has reiterated its Buy rating on KalVista Pharmaceuticals (KALV.US) and maintained its target price of $42. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells 174,645 Shares of Stock
Venrock Healthcare Capital Par, a major shareholder in KalVista Pharmaceuticals (NASDAQ:KALV), sold 174,645 shares of the company's stock for over $2.9 million on March 25th, and an additional 39,986 shares for over $730,000 on March 26th. Following these transactions, Venrock Healthcare Capital Par's ownership in KalVista Pharmaceuticals decreased by 3.29%. The article also highlights recent positive analyst sentiment, with Stifel Nicolaus and Needham & Company raising their price targets for KALV.
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS)
This article highlights bullish sentiments from three analysts on healthcare companies Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV), and Ionis Pharmaceuticals (IONS). Bank of America Securities analysts Alec Stranahan, Tazeen Ahmad, and Jason Gerberry each maintained Buy ratings on these respective companies, providing price targets and discussing their average returns and success rates within the healthcare sector. The article also notes the current analyst consensus for each stock, indicating Strong Buy ratings and significant upside potential.
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares
Venrock Healthcare Capital Partners funds have trimmed their stake in KalVista Pharmaceuticals (KALV) by selling 214,631 shares in open-market transactions on March 25-26, at prices ranging from $16.95 to $19.12 per share. Following these sales, the affiliated funds still indirectly hold approximately 5.09 million shares. The filing clarifies that associated management entities and individuals beneficially own these securities only to the extent of their indirect pecuniary interest.
EKTERLY drives $49.1M revenue as KalVista (Nasdaq: KALV) reports net loss
KalVista Pharmaceuticals reported $49.1 million in global net product revenue for EKTERLY during the eight-month transition period ending December 31, 2025. Despite strong commercial adoption with 1,702 US patient start forms and international launches, the company posted a net loss of $109.5 million for the period. KalVista plans to expand EKTERLY access worldwide and advance pediatric filings, aiming for profitability funded by current cash and projected revenues.
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet
Wall Street analysts project a potential 117.1% upside for KalVista Pharmaceuticals (KALV), with an average price target of $28.00. While the substantial predicted gain is enticing, investors are advised to consider the company's fundamentals and the broader market before making investment decisions. The article suggests using the Zacks Rank as a tool to evaluate stocks, noting that stocks with a Zacks Rank #1 or #2 tend to outperform.
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative
KalVista Pharmaceuticals (KALV) reported Q4 FY 2025 revenue of US$59.9 million but still posted a basic EPS loss of US$0.10, indicating the company remains in an investment phase with significant ongoing losses. The article explores the contrasting optimistic (bullish) and pessimistic (bearish) narratives regarding KALV's future profitability, highlighting the gap between its growing revenue and substantial operating costs. Despite a high Price-to-Book multiple, a discounted cash flow valuation suggests the stock might be undervalued by some analysts, creating a mixed valuation signal for investors.
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target
H.C. Wainwright reiterated a Buy rating on Kalvista Pharmaceuticals Inc (NASDAQ:KALV) with a $37 price target, citing strong demand for its drug Ekterly. The firm emphasizes that Ekterly sales, particularly increasing refills, indicate it's becoming the preferred on-demand therapy for hereditary angioedema. This positive outlook is supported by Ekterly's significant revenue in its first year and upward earnings revisions by analysts.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2025 Earnings Call Transcript
KalVista Pharmaceuticals reported its Q1 2025 earnings, highlighting the successful multinational launch of EKTERLY, their oral on-demand treatment for hereditary angioedema (HAE). The company saw $49 million in revenue from launch through December 31, 2025, with strong early adoption in the U.S. and Germany. KalVista plans to expand EKTERLY's use to pediatric patients by submitting an NDA in Q3 2026 and expects operating expenses to remain consistent, aiming for profitability under its current plan.
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative
KalVista Pharmaceuticals (KALV) reported Q4 FY 2025 revenue of US$59.9 million but still incurred a net loss of US$5.4 million, indicating it remains in an investment phase despite a significant increase from Q3 revenue. The company’s substantial losses of US$164.3 million over the past 12 months challenge bullish forecasts of profitability, while skeptics highlight the wide gap between limited commercial scale and high operating costs. Conflicting valuation signals, including a high price-to-book ratio and an optimistic DCF fair value, suggest a split market perception of its long-term potential.
Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch
Citizens has lowered its price target for Kalvista Pharmaceuticals Inc (NASDAQ:KALV) to $28.00 from $29.00, while maintaining a Market Outperform rating, noting the stock's strong momentum and recent performance near its 52-week high. This adjustment follows the consistent launch and sales of Ekterly, which generated $49 million globally by year-end 2025, demonstrating continued market adoption despite newer prophylactic drugs. The firm projects 2026 revenue of $245 million, significantly above the consensus of $183 million, based on positive commercial trajectory and analyst revisions.
Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch
Citizens has lowered its price target for KalVista Pharmaceuticals (NASDAQ:KALV) to $28.00 from $29.00, affirming a Market Outperform rating following steady launch results for its product Ekterly. Despite the price target cut, the stock shows strong momentum, having risen 38% in six months, with other analysts maintaining a bullish outlook. KalVista's Ekterly demonstrated $49.1 million in global net product revenue for the eight-month period ending December 31, 2025, and continues to expand its patient reach and prescriber base in the U.S., Germany, and Japan.
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
KalVista Pharmaceuticals (Nasdaq: KALV) announced its financial results for the eight months ended December 31, 2025, reporting $49.1 million in global net product revenue for EKTERLY®. The company highlights strong adoption of EKTERLY, its oral on-demand treatment for HAE, with 1,702 patient start forms in the US and launches in Germany and Japan. KalVista also provided updates on its clinical and regulatory progress, including the completion of enrollment for the KONFIDENT-KID trial for pediatric HAE patients.
Kalvista stock price target raised to $42 by Stifel on Ekterly demand
Stifel raised its price target on Kalvista Pharmaceuticals Inc (KALV) shares to $42 from $39, maintaining a Buy rating, due to strong demand for Ekterly, its oral treatment for hereditary angioedema. The company reported $49 million in full-year 2025 revenue and has seen significant patient growth for Ekterly. This positive performance has led to a 36% increase in share price over the past six months and upward earnings revisions by analysts.
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Raises Target Price to $42
Stifel has reiterated its Buy rating for KalVista Pharmaceuticals (KALV.US) and increased its target price to $42. This update reflects the firm's continued positive outlook on the pharmaceutical company's prospects.
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
KalVista Pharmaceuticals reported its financial results for the eight months ended December 31, 2025, announcing $49.1 million in global net product revenue for EKTERLY (sebetralstat) and continued strong adoption for the oral HAE treatment. The company also provided a corporate update, including commercial progress in the US, Germany, and Japan, as well as regulatory advancements for EKTERLY, such as timely completion of its pediatric trial and plans for a US NDA filing. KalVista anticipates current cash and projected revenues will fund the company through profitability.
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
KalVista Pharmaceuticals, Inc. announced a conference call and webcast for Wednesday, March 25, 2026, at 8:30 a.m. ET. The event will cover the company's eight months fiscal year 2025 financial results and provide a corporate update. An archived replay will be available on their investor relations website shortly after the event.
Tudor Investment Corp ET AL Makes New $24.36 Million Investment in KalVista Pharmaceuticals, Inc. $KALV
Tudor Investment Corp ET AL has made a new $24.36 million investment in KalVista Pharmaceuticals (NASDAQ:KALV), acquiring 2,000,000 shares, representing 3.96% of the company. Despite recent insider sales by CFO Brian Piekos and director Paul K. Audhya, analysts maintain a "Moderate Buy" rating with an average target price of $29.40, with several firms raising their price objectives. The specialty pharmaceutical company focuses on developing small-molecule protease inhibitors for orphan and specialty disease indications.
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals will present new EKTERLY® (sebetralstat) data at the 2026 Global Angioedema Leadership Conference in Madrid, Spain. Five abstracts, including a late-breaking oral presentation on sebetralstat for hereditary angioedema (HAE) attacks in children aged 2-11 (KONFIDENT-KID trial), will be featured. Other presentations will cover patient satisfaction and treatment patterns of sebetralstat, as well as barriers to and anxiety associated with injectable on-demand therapies for HAE.
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals is set to present new data on EKTERLY® (sebetralstat) at the 2026 Global Angioedema Leadership Conference. This includes interim data from the KONFIDENT-KID trial for children aged 2-11, accepted for a late-breaking oral presentation, and several poster presentations addressing patient satisfaction, treatment patterns, and barriers to HAE treatment. EKTERLY® is the first and only oral on-demand treatment for HAE, with plans for expanded use to younger children in 2026.
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals announced that five abstracts, including a late-breaking submission on interim data from the KONFIDENT-KID trial for sebetralstat in children with hereditary angioedema (HAE), have been accepted for presentation at the 2026 Global Angioedema Leadership Conference. The presentations will cover findings on sebetralstat for HAE attacks in children aged 2-11, patient satisfaction and treatment patterns in adults, and insights on barriers to treatment and anxiety in patients using injectable on-demand therapies. EKTERLY (sebetralstat) is the first and only oral on-demand treatment for HAE, with plans for a US regulatory filing in 2026 to expand its use to children aged 2-11.
How (KALV) Movements Inform Risk Allocation Models
This article analyzes Kalvista Pharmaceuticals Inc. (NASDAQ: KALV) using AI models to provide trading strategies. It highlights a weak near-term sentiment but strong mid and long-term outlook, identifying an exceptional risk-reward setup targeting a 16.1% gain. The report offers specific position, momentum breakout, and risk hedging strategies for various risk profiles.
KalVista Pharmaceuticals Inc (HAM:4XC1) Dividend
This article provides a summary page for KalVista Pharmaceuticals Inc (HAM:4XC1) on GuruFocus. It includes key financial metrics like market cap, P/E ratio (at loss), and P/B ratio. The page also notes severe warning signs detected by GuruFocus for the stock and provides an overview of available tools and data.
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet
This article analyzes KalVista Pharmaceuticals (KALV) stock performance and future potential, as predicted by Wall Street analysts. Experts anticipate a significant surge of 117.1% in KALV's stock value, based on recent upgrades and financial forecasts. Investors are advised to review this information before making any investment decisions.
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet
Wall Street analysts project a potential 117.1% upside for KalVista Pharmaceuticals (KALV) based on their average 12-month price target. The company recently received an average "Buy" rating from four analysts, with individual price targets ranging from $14.50 to $27.00. Investors might find this information useful before making investment decisions.
Kalvista Pharmaceuticals To Report Eight Months Fiscal Year 2025 Financial Results And Provide Corporate Update On March 25, 2026
Kalvista Pharmaceuticals is scheduled to report its eight months fiscal year 2025 financial results and provide a corporate update on March 25, 2026. This announcement, made by Reuters, indicates an upcoming financial disclosure for the company. The information suggests investors and stakeholders should anticipate updates regarding the company's performance and future outlook.
Kalvista Pharmaceuticals Inc (KALV) announced that it will release its financial results for the first eight months of fiscal year 2025 on March 25, 2026, and will also provide an update on the latest developments in the company's business.
Kalvista Pharmaceuticals Inc (KALV) is set to release its financial results for the first eight months of fiscal year 2025 on March 25, 2026, along with a business update. The biopharmaceutical company has adjusted its financial reporting period, leading to market speculation. Analysts will focus on the clinical progress and regulatory timeline for sebetralstat (KVD824), its core drug candidate for hereditary angioedema (HAE).
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
KalVista Pharmaceuticals, Inc. announced it will host a conference call and webcast on March 25, 2026, at 8:30 a.m. ET to discuss its eight months fiscal year 2025 financial results and provide a corporate update. The event will be accessible via the Investors section of the Company's website, with an archived replay available afterward. KalVista is a global pharmaceutical company focused on rare diseases, known for developing EKTERLY®, an oral treatment for hereditary angioedema.
KalVista Pharmaceuticals (KALV) Projected to Post Quarterly Earnings on Tuesday
KalVista Pharmaceuticals (KALV) is expected to announce its Q4 2026 earnings before market open on Tuesday, March 24th, with analysts projecting an EPS of ($0.5263) and revenue of $32.29 million. The company currently holds a "Moderate Buy" rating from analysts, with an average price target of $29.40. Insider trading activity in the last 90 days shows sales of 33,378 shares valued at $522,290.
Boxer Capital Management LLC Decreases Position in KalVista Pharmaceuticals, Inc. $KALV
Boxer Capital Management LLC significantly reduced its stake in KalVista Pharmaceuticals (NASDAQ:KALV) by 78.2% in the third quarter, selling 73,000 shares. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating for KalVista, with a price target of $29.40, and several firms have raised their price targets. Company insiders have been net sellers in the last 90 days, offloading 33,378 shares, and currently own about 4.30% of the stock.
Suvretta Capital Management LLC Reduces Position in KalVista Pharmaceuticals, Inc. $KALV
Suvretta Capital Management LLC decreased its stake in KalVista Pharmaceuticals (NASDAQ:KALV) by 3.8% in the third quarter, now owning 4,768,712 shares valued at approximately $58.1 million. Despite this reduction, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and an average target price of $29.40. Recent insider selling by Nicole Sweeny and CFO Brian Piekos also occurred, though insiders still collectively own about 4.3% of the company.
KalVista Pharmaceuticals executive Nicole Sweeny honored as MMM Women of Distinction award recipient
KalVista Pharmaceuticals announced that Nicole Sweeny has been recognized as a Women of Distinction honoree by MMMnews. Sweeny, who leads TeamKalVista, is celebrated for her advocacy within the hereditary angioedema community and her leadership within the company. KalVista Pharmaceuticals praised her mentorship and visionary contributions and invited the broader community to join in celebrating this achievement.
KalVista Stock Pre-Market (-0.2%): CEO Stock Sale for Tax Purposes Reported in SEC Filing
KalVista Pharmaceuticals (KALV) stock is down 0.2% in pre-market trading after a Form 4 SEC filing revealed CEO Benjamin Palleiko sold 6,693 shares. The company clarified this was a non-discretionary "sell to cover" transaction to meet tax obligations from vested equity awards, not a signal of lack of confidence, as his remaining holdings are substantial. The sale of approximately $107,000 is considered routine financial maintenance and immaterial compared to his total post-transaction holdings of $7.27 million.
Blue Owl Capital Holdings LP Invests $1.52 Million in KalVista Pharmaceuticals, Inc. $KALV
Blue Owl Capital Holdings LP has acquired a new stake of 125,000 shares, valued at $1.52 million, in KalVista Pharmaceuticals, Inc. during the third quarter. While institutional investment is growing, company insiders have been net sellers in recent months. Analysts maintain a "Moderate Buy" rating for KALV with a consensus price target of $29.40.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of "Moderate Buy" from Analysts
KalVista Pharmaceuticals (NASDAQ:KALV) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year price target of $29.40. Despite this positive outlook, recent insider transactions show CEO Benjamin L. Palleiko and another insider selling a significant number of shares, reducing total insider ownership to 4.30%. The company, a clinical-stage biotechnology firm, specializes in therapies for hereditary angioedema (HAE) and diabetic macular edema, with its shares opening at $16.23 on Friday.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals has reported inducement grants to new employees in compliance with Nasdaq Listing Rule 5635(c)(4). These grants, which include options to purchase common stock and restricted stock units, were approved by the company's compensation committee and are intended to align new hires with KalVista's long-term performance. The move reflects typical compensation strategies for publicly traded companies attracting talent.
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Crosses Above 50-Day Moving Average - Here's Why
KalVista Pharmaceuticals (NASDAQ:KALV) stock has crossed above its 50-day moving average, trading at $15.61 with significant volume. Analysts hold a "Moderate Buy" consensus rating with a $29.40 price target, and HC Wainwright recently raised its target to $37. However, insider selling by the CEO and another insider recently occurred, with 33,979 shares sold in the past 90 days.
KalVista presents sebetralstat data showing early treatment impact
KalVista Pharmaceuticals Inc. presented positive data for its oral hereditary angioedema (HAE) treatment, sebetralstat, at two medical conferences, highlighting its effectiveness in early attack treatment and high patient satisfaction. The data showed early intervention significantly improves symptom relief, leading to increased use of sebetralstat and reduced reliance on conventional injectable treatments. The company also reported strong preliminary Q4 2025 revenue for EKTERLY, another HAE treatment, significantly exceeding analyst expectations, and plans a US regulatory filing for sebetralstat to expand its use to children.
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
KalVista Pharmaceuticals presented new data from its sebetralstat clinical trial program at recent medical meetings, highlighting high patient satisfaction and evolving treatment trends for hereditary angioedema (HAE). The data suggest that access to oral sebetralstat (EKTERLY) encourages earlier intervention in HAE attacks, leading to improved outcomes and a strong patient preference over injectable treatments. Early treatment within 30 minutes of attack onset was identified as the most significant predictor of achieving earlier symptom relief.
